Non-invasive F-19 MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours

T Dresselaers, J Theys, S Nuyts, B Wouters, E de Bruijn, J Anne, P Lambin, P Van Hecke, W Landuyt*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Downloads (Pure)

Abstract

The aim of this study was to evaluate the applicability of fluorine-19 magnetic resonance spectroscopy (F-19 MRS) for monitoring in vivo the conversion of 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU) after using an attenuated Salmonella Typhimurium strain recombinant to provide cytosine deaminase (TAPET-CD). The F-19 MRS measurements were done on mice bearing the human colon tumour xenograft (HCT116). The intratumoural conversion is greater when TAPET-CD/5-FC is delivered intratumourally (i.tu.) than when TAPET-CD is delivered intravenously (i.v.) and 5-FC intraperitoneally (i.p.). Repeat measurements of the same tumour also yielded important information on the tumour colonization by TAPET-CD through the correlated 5-FC to 5-FU conversion efficacy. The in vivo MRS spectra were confirmed by in vitro 19 F MRS of perchloric acid extracts of the tumour tissue. No 5-FU metabolites were detectable in vivo in the tumours. However, the in vitro measurements revealed, besides 5-FC and 5-FU, the presence of small amounts of catabolites. Finally, spectra obtained in vitro from liver extracts of tumour-bearing mice treated i. tu. with TAPET-CD/5-FC showed no 5-FU and only little amounts of catabolites. Our data illustrate most importantly the potential of F-19 MRS to monitor biologically-based treatments involving cytosine deaminase.

Original languageEnglish
Pages (from-to)1796-1801
Number of pages6
JournalBritish Journal of Cancer
Volume89
Issue number9
DOIs
Publication statusPublished - 3 Nov 2003

Keywords

  • F-19 MRS
  • 5-fluorouracil
  • cytosine deaminase
  • xenograft human tumour
  • mouse
  • recombinant bacteria
  • MAGNETIC-RESONANCE-SPECTROSCOPY
  • CANCER GENE-THERAPY
  • CYTOSINE DEAMINASE
  • IN-VIVO
  • NMR-SPECTROSCOPY
  • INTRATUMORAL PHARMACOKINETICS
  • METHOTREXATE PRETREATMENT
  • METABOLITE PATTERNS
  • ANAEROBIC-BACTERIA
  • PRODRUG ACTIVATION

Cite this